News Releases

Date Title and Summary
Toggle Summary electroCore Announces Listing Transfer to the Nasdaq Capital Market
ROCKAWAY, N.J. , June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq
Toggle Summary electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
ROCKAWAY, N.J. , May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, N.J. , May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be presenting at the H.C. Wainwright Global Investment Conference and LD Micro
Toggle Summary electroCore Announces Record First Quarter 2022 Financial Results
First quarter 2022 net sales of $1.9 million , approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ROCKAWAY, N.J. , May 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore to Announce First Quarter 2022 Financial Results on May 5
ROCKAWAY, N.J. , April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022 , after the close of the market on Thursday, May 5, 2022 .
Toggle Summary electroCore Completes Sale of New Jersey Tax Benefits
ROCKAWAY, N.J. , April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its available tax benefits through the New Jersey Economic Development Authority’s Technology Business Tax
Toggle Summary electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
ROCKAWAY, N.J. , April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published results from an investigator-initiated trial, SAVIOR-1, a prospective, randomized, controlled study
Toggle Summary gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
ROCKAWAY, N.J. , April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.  (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for further study under the United States Department of Defense Biotech Optimized for Operational
Toggle Summary electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance
Record r evenue from product sales will be approximately $1.9M ; approximately 60% growth over first quarter 2021 March 31, 2022 , cash balance of approximately $29.9M ROCKAWAY, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage
Toggle Summary electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
ROCKAWAY, N.J. , April 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Teijin Limited (Teijin), a global conglomerate based in Japan offering advanced solutions